Summary
Biogen Idec Inc. (BIIB) reported strong financial performance for the second quarter and first six months of 2014, driven by significant revenue growth across key products, particularly TECFIDERA. Total revenues increased by 40.5% for the quarter and 55.6% year-to-date, reaching $2.42 billion and $4.55 billion, respectively. This growth translated into substantial increases in profitability, with net income attributable to Biogen Idec Inc. up 45.6% for the quarter to $714.5 million and diluted earnings per share rising by 46.4% to $3.01. The company highlighted robust sales of TECFIDERA, which saw a 264.6% increase in Q2 2014 revenues, becoming a major growth driver. TYSABRI also showed strong performance with a 37.9% revenue increase. While AVONEX revenues remained stable, the company noted shifts in the Multiple Sclerosis market due to the adoption of oral therapies. The launch of new products like ALPROLIX also contributed to revenue growth. Investments in research and development increased significantly, reflecting the company's commitment to pipeline advancement, particularly in neurodegenerative diseases and autoimmune disorders. Despite increased operating expenses, including higher R&D and SG&A costs, the company maintained strong operational efficiency and generated robust operating cash flows, underscoring its healthy financial position and capacity for future growth.
Financial Highlights
54 data points| Revenue | $2.42B |
| Cost of Revenue | $291.89M |
| Gross Profit | $2.13B |
| SG&A Expenses | $576.62M |
| Operating Expenses | $1.44B |
| Operating Income | $988.73M |
| Interest Expense | $7.10M |
| Net Income | $714.50M |
| EPS (Basic) | $3.02 |
| EPS (Diluted) | $3.01 |
| Shares Outstanding (Basic) | 236.70M |
| Shares Outstanding (Diluted) | 237.40M |
Key Highlights
- 1Total revenues increased by 40.5% to $2.42 billion in Q2 2014 and by 55.6% to $4.55 billion in the first six months of 2014.
- 2Net income attributable to Biogen Idec Inc. grew by 45.6% in Q2 2014 to $714.5 million, with diluted EPS rising 46.4% to $3.01.
- 3TECFIDERA revenue surged by 264.6% in Q2 2014 to $700.4 million, becoming a significant growth driver.
- 4TYSABRI revenues increased by 37.9% to $533.4 million in Q2 2014.
- 5Research and development expenses increased by 36.6% in Q2 2014, reflecting continued investment in pipeline development.
- 6Operating cash flow was strong, reaching $1.1 billion for the first six months of 2014.
- 7The company successfully launched new products ALPROLIX and ELOCTATE in Q2 2014.